Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Utility of CD56 immunohistochemical studies in follow-up of plasma cell myeloma. Am J Clin Pathol 2009 Jul;132(1):60-6

Date

10/30/2009

Pubmed ID

19864234

DOI

10.1309/AJCPOP7TQ3VHHKPC

Scopus ID

2-s2.0-67650471360   22 Citations

Abstract

Although 70% to 80% of plasma cell myelomas (PCMs) express CD56, few data are available on the usefulness of CD56 immunohistochemical analysis in assessing residual disease. We retrospectively reviewed 127 PCM posttreatment bone marrow (BM) specimens, classifying them as positive or negative for residual disease (independent of CD56 immunohistochemical studies) based on abnormal plasma cell (PC) morphologic features or flow cytometry (FC) and/or light chain restriction by immunohistochemical studies (conventional criteria). CD56 immunohistochemical analysis was performed on these and 20 negative lymphoma staging BM specimens. Of 127 BM specimens, 74 were positive and 53 were negative for residual PCM by conventional criteria. Of 74 BM specimens positive by conventional criteria, 59 (80%) demonstrated CD56 (strong+) PCs in clusters and/or with cytologic atypia. Of the 53 BM specimens negative by conventional criteria, 3 showed CD56 (strong+) morphologically atypical PCs in clusters or scattered. CD56 immunohistochemical analysis is useful for detecting residual PCM, particularly in morphologically equivocal cases in which light chain restriction cannot be demonstrated, and may serve as a potential response criterion.

Author List

Harrington AM, Hari P, Kroft SH

Authors

Alexandra M. Harrington MD Professor in the Pathology department at Medical College of Wisconsin
Steven Howard Kroft MD Chair, Professor in the Pathology department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adult
Aged
Biomarkers, Tumor
Bone Marrow Cells
CD56 Antigen
Female
Flow Cytometry
Fluorescent Antibody Technique, Indirect
Follow-Up Studies
Humans
Immunoenzyme Techniques
Immunoglobulin lambda-Chains
Male
Middle Aged
Multiple Myeloma
Neoplasm, Residual
Plasma Cells
Prognosis
Retrospective Studies